In this episode of Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership talks to Mike Clayman, CEO and co-founder of Flexion Therapeutics, about how the COVID-19 pandemic has affected their employees, distribution of their lead product Zilretta and their clinical trials. This discussion includes how Flexion Therapeutics has been able to return to some form of normality for both their employees, and their therapies, with the sales and distribution of Zilretta reaching pre-COVID-19 levels. Mike explores how they were able to raise over $100million dollars in May, despite the disruption, due to the believe in both Zilretta, and their exciting pipeline products that have been able to restart clinical trial research. They also discuss how the industry has embraced telemedicine during this time, and the belief that it’s here to stay. Watch the full episode to find out more.
